A precision genome-insertion platform for crops that uses large serine integrases to deliver large DNA payloads into predefined safe-harbor sites, enabling stable, site-specific transgene insertion in Camelina and Brassica without random integration variability.
This research program develops a precision tool for inserting large DNA sequences into specific, pre-chosen locations in crop genomes. Unlike traditional transgenesis, which relies on random integration and produces unpredictable expression, this approach uses large serine integrases (LSIs)—enzymes that evolved to splice entire phage genomes into host DNA at specific attachment sites. By matching thousands of naturally occurring integrase specificities to accessible, single-copy safe-harbor regions in Camelina sativa and Brassica genomes, the platform enables clean, targeted insertion of sizable genetic payloads. The technology also includes a mechanism for removing vector backbone and integrase genes, leaving a reusable landing pad for sequential, modular insertions.
Core mechanism:
Bioinformatic targeting pipeline:
Delivery and validation:
Clean insertion and reusability:
The program is at an early-to-mid research stage. LSI biochemistry and mechanism are well established in the Rice laboratory. The current work focuses on bioinformatic identification of suitable integrase-genome site pairs, validation of activity in E. coli, and initial plant insertion testing in Camelina. Future validation will extend the approach to Brassica and demonstrate clean, multiplexed insertions at predefined loci. The technology is not yet commercially deployed but is advancing toward demonstrated site-specific insertion in a crop species.
The University of Chicago is a private institution that brings together the power of 140 institutes and centers including an NCI-designated Comprehensive Cancer Center, a microbiome focused center, two U.S. Department of Energy National Labs (Argonne National Laboratory and Fermi National Accelerator Laboratory) and the Marine Biological Laboratory, making it a truly powerful research and development enterprise of over 15,000 faculty and research staff. UChicago is home to the Pritzker School of Molecular Engineering, launched in 2011 as the first and only engineering school in the U.S. focused entirely on molecular engineering with one of the major focused areas in immunoengineering, and a core partner of the Chan Zuckerberg (CZ) Biohub - Chicago. Researchers at UChicago have pioneered breakthroughs including discovering the link between cancer and genetics, establishing revolutionary theories of economics, and developing tools to enhance urban schooling. UChicago researchers are at the forefront of fields ranging from quantum computing, data science and artificial intelligence, to the modeling and synthesis of advanced materials, to oncology and neuroscience.